Ferring Favorite To Get First Approval For Microbiota-Based Therapy

If all goes well, 2020 could see the Swiss firm's Rebiotix subsidiary get a green light from the FDA for its recurrent Clostridioides difficile fecal product.

Race
Ferring ahead of the field for microbiome-based therapies • Source: Shutterstock

Ferring Pharmaceuticals AS is in pole position to be first pharmaceutical company to file a treatment that harnesses the power of the human microbiome, with a potential launch pencilled in next year for RBX2660 for reducing recurrent Clostridioides difficile (C diff) infection in adults.

The privately owned Swiss firm, best known for its reproductive medicines, has made the microbiome a key element of its...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category